Intra-Cellular Therapies (ITCI) Tops Q4 Loss Expectations

February 25, 2016 8:55 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.67), $0.23 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $30.66 million versus the consensus estimate of $60 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

The Children's Investment Fund (TCI), Earnings